Dr. Coleman is an assistant professor at the Boston University School of Medicine (BUSM). She received her doctorate from the BUSM Department of Microbiology, and completed her postdoctoral fellowship at the Boston Children’s Hospital in the Department of Pathology/Transfusion Medicine. She is trained in both the biomedical sciences and science pedagogy. As a microbiologist, Dr. Coleman’s research focuses on bacterial pathogens. She has served as principal investigator and collaborator with other investigators on several projects and has published in a wide range of peer-reviewed journals, including Journal of Infectious Diseases, Mucosal Immunology, and Proceedings of the National Academy of Sciences. She has been invited to give several professional seminars at national and international meetings, including the mini-symposia at the American Thoracic Society International Conference in San Diego, California. Dr. Coleman is also the recipient of numerous awards for research excellence, including a National Research Service Award Fellowship from the National Institutes of Health, the BU President’s Award for Outstanding Biomedical Research, and the 2014 Raymond W. Sarber Award.
Dr. Coleman is also the director of the Biomedical Laboratory and Clinical Sciences program, the medical school’s only degree granting undergraduate program in the biomedical sciences. As an educator and researcher, Dr. Coleman draws from her previous K-12 and higher education teaching experiences and training to establish new and innovative strategies designed to prepare undergraduates (especially from underrepresented backgrounds) to enter and succeed in the biomedical/STEM workforce. Her specific areas of science education research are: 1) educational interventions that enhance diversity and equity in science education; 2) effective learning and teaching methods in laboratory sciences; and 3) cognitive strategies in science learning.
- Assistant Professor, Sociomedical Sciences, Boston University School of Medicine
- Boston University School of Medicine, PhD
- Harvard University, MA
- Boston University, BA
- BT 301
- Published on 6/1/2018
Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT, Mizgerd JP, Hildebrand W, Kronenberg M, Lewinsohn DM, Harriff MJ. Riboflavin Metabolism Variation among Clinical Isolates of Streptococcus pneumoniae Results in Differential Activation of Mucosal-associated Invariant T Cells. Am J Respir Cell Mol Biol. 2018 06; 58(6):767-776. PMID: 29356555.
- Published on 8/15/2017
Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP. Capacity of Pneumococci to Activate Macrophage Nuclear Factor ?B: Influence on Necroptosis and Pneumonia Severity. J Infect Dis. 2017 Aug 15; 216(4):425-435. PMID: 28368460.
- Published on 5/17/2017
Smith NM, Wasserman GA, Coleman FT, Hilliard KL, Yamamoto K, Lipsitz E, Malley R, Dooms H, Jones MR, Quinton LJ, Mizgerd JP. Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia. Mucosal Immunol. 2018 Jan; 11(1):220-235. PMID: 28513594.
- Published on 10/9/2014
Hyatt LD, Wasserman GA, Rah YJ, Matsuura KY, Coleman FT, Hilliard KL, Pepper-Cunningham ZA, Ieong M, Stumpo DJ, Blackshear PJ, Quinton LJ, Mizgerd JP, Jones MR. Myeloid ZFP36L1 does not regulate inflammation or host defense in mouse models of acute bacterial infection. PLoS One. 2014; 9(10):e109072. PMID: 25299049.
- Published on 2/5/2007
Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun. 2007 Apr; 75(4):1598-608. PMID: 17283089.
- Published on 11/1/2004
Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 1; 173(9):5671-8. PMID: 15494518.
- Published on 7/1/2004
Priebe GP, Dean CR, Zaidi T, Meluleni GJ, Coleman FT, Coutinho YS, Noto MJ, Urban TA, Pier GB, Goldberg JB. The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun. 2004 Jul; 72(7):4224-32. PMID: 15213167.
- Published on 7/1/2003
Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun. 2003 Jul; 71(7):3875-84. PMID: 12819072.
- Published on 3/1/2003
Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun. 2003 Mar; 71(3):1453-61. PMID: 12595463.
- Published on 2/10/2003
Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1949-54. PMID: 12578988.
View 3 more publications: View full profile at BUMC